Compounds > 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and penicillamine

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with penicillamine in 1 studies

Compound Research Comparison

Studies
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Trials
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Recent Studies (post-2010)
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Studies
(penicillamine)		Trials
(penicillamine)		Recent Studies (post-2010) (penicillamine)
33040337,415312442

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonini, A; Kirsch, CM; Kraft, E; Leenders, KL; Oertel, WH; Schwarz, J; Tatsch, K; Vogl, T1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and penicillamine

ArticleYear
Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
    Neurology, 1994, Volume: 44, Issue:6

    Topics: Adolescent; Adult; Benzamides; Brain; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Penicillamine; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon

1994